You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,370,527


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,370,527
Title:Amelioration of intestinal fibrosis and treatment of Crohn\'s disease
Abstract: Methods of treating patients with inflammatory bowel disease, intestinal fibrosis, or Crohn\'s disease involve administering a therapeutic amount of CARD-024 or related compound.
Inventor(s): Simpson; Robert U. (Ann Arbor, MI), Higgins; Peter D. R. (Ann Arbor, MI), Johnson; Laura A. (Ann Arbor, MI)
Assignee: The Regents Of The University Of Michigan (Ann Arbor, MI)
Application Number:14/134,587
Patent Claims:1. A method of treating a subject to relieve the symptoms of inflammatory bowel disease, the method comprising administering to the subject a therapeutically effective dose of a compound of Formula (I) ##STR00004## wherein Et is ethyl, wherein the dashed line indicates a single bond between carbon 22 and carbon 23, and wherein the configuration at carbon 24 to which Et is attached is in the R configuration or the S configuration.

2. The method according to claim 1, wherein the compound of Formula (I) comprises (1S,3R)-(5Z,7E)-9,10-secositosta-5,7,10(19)-triene-1,3-diol (CARD-024).

3. The method according to claim 1, comprising administering a composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

4. The method according to claim 3, wherein the composition comprises a tablet.

5. The method according to claim 1, wherein the subject is diagnosed with Crohn's disease.

6. The method according to claim 2, comprising administering the effective dose orally.

7. The method of claim 2, wherein the daily dose is from 10 mcg to 1000 mcg.

8. The method of claim 2, further comprising administering to the patient a compound selected from infliximab, adelimumab, certolizumab (CDP-870), interleukin-10, interleukin-4,6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluor- ophenyl)-3-pyridinecarboxamide (VX 702), 6-Chloro-5-[[(2R,5S)-4-[(4-flurophenyl)methyl]-2,5-dimethyl-1-piperazinyl- ]carbonyl]-N,N, 1-trimethyl-.alpha.-oxo-1H-Indole-3-acetamide (SCIO 469), doramapimod, ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy]phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)) (DPC 333), pranalcasan, mycophenolate, merimepodib, cyclosporine, tacrolimus, pimecrolimus, 6[(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid]-Cyclosporin A (ISAtx247), 5-aminosalicylic acid, mesalamine, sulfasalazine, balsalazide disodium, olsalazine sodium, methotrexate, azathioprine, and alosetron.

9. The method of claim 2, comprising administering to the patient a composition comprising CARD-024 and a compound selected from infliximab, adelimumab, certolizumab (CDP-870), interleukin-10, interleukin-4,6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluor- ophenyl)-3-pyridinecarboxamide (VX 702), 6-Chloro-5-[[(2R,5S)-4-[(4-flurophenyl)methyl]-2,5-dimethyl-1-piperazinyl- ]carbonyl]-N,N, 1-trimethyl-.alpha.-oxo-1H-Indole-3-acetamide (SCIO 469), doramapimod, ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy]phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)) (DPC 333), pranalcasan, mycophenolate, merimepodib, cyclosporine, tacrolimus, pimecrolimus, 6-[(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid]-Cyclosporin A (ISAtx247), 5-aminosalicylic acid, mesalamine, sulfasalazine, balsalazide disodium, olsalazine sodium, methotrexate, azathioprine, and alosetron.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.